Related Experiment Video

Updated: Aug 9, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?

C J Desmet1, D S Peeper

  • 1Division of Molecular Genetics, The Netherlands Cancer Institute, Amsterdam.

Cellular and Molecular Life Sciences : CMLS
|March 29, 2006
PubMed

Insights

The neurotrophic receptor tyrosine kinase TrkB promotes cancer growth and metastasis. Inhibiting TrkB shows promise as a novel anti-cancer therapy, with clinical trials underway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Altered signaling of neurotrophic receptor tyrosine kinase TrkB is implicated in tumor formation and metastasis.
  • TrkB and its ligand BDNF are overexpressed in various human cancers, potentially driving tumor expansion and treatment resistance.

Purpose of the Study:

  • To review the role of TrkB in tumorigenesis and metastasis.
  • To discuss TrkB as a potential drug target for cancer therapy.
  • To highlight ongoing research and remaining questions regarding TrkB inhibition in cancer.

Main Methods:

  • Review of preclinical models and existing literature on TrkB signaling in cancer.
  • Analysis of TrkB's function in suppressing anoikis (detachment-induced apoptosis).
  • Evaluation of Trk inhibitors in tumor xenograft models.

Main Results:

  • TrkB overexpression is linked to aggressive tumor phenotypes and metastasis.
  • TrkB inhibition demonstrates efficacy in preclinical cancer models.
  • Pharmacological Trk inhibitors show promise for anti-tumor strategies.

Conclusions:

  • TrkB is a significant contributor to cancer progression and metastasis.
  • TrkB inhibition represents a promising therapeutic strategy currently under clinical investigation.
  • Further research is needed to fully evaluate TrkB as a cancer therapeutic target.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Concept Videos

Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...